Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion

Profluent announced a multi-program research collaboration with Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines. The deal is a meaningful validation of Profluent's AI biotech platform and could create significant long-term upside if programs advance successfully. For Eli Lilly, the partnership expands its genetic medicines pipeline with external AI capabilities.

Analysis

Profluent announced a multi-program research collaboration with Eli Lilly worth up to $2.25 billion to develop AI-designed enzymes for genetic medicines. The deal is a meaningful validation of Profluent's AI biotech platform and could create significant long-term upside if programs advance successfully. For Eli Lilly, the partnership expands its genetic medicines pipeline with external AI capabilities.